Tivozanib is an orally available, selective VEGFR inhibitor with IC₅₀ values of 0.21, 0.16, and 0.24 nM for VEGFR1, VEGFR2, and VEGFR3, respectively.^1,2 It can also inhibit c-Kit and PDGFRβ with IC₅₀ values of 1.63 and 1.72 nM, respectively.² When administered to athymic rats, tivozanib was shown to decrease the microvessel density within tumor xenografts and attenuate VEGFR2 phosphorylation levels in tumor endothelium.² It also displays antitumor activity against a wide variety of human tumor xenografts, including lung, breast, colon, ovarian, pancreas, and prostate cancer.²

≥95%

Store at -20℃

AV-951;KRN 951;

1.Bhargava, P. and Robinson, M.O. Development of second-generation VEGFR tyrosine kinase inhibitors: Current status. Curr.Oncol.Rep. 13(2), 103-111 (2011).

2.Nakamura, K.,Taguchi, E.,Miura, T., et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 66(18), 9134-9142 (2006).